This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.
With this fast track designation, the combination of ublituximab and umbralisib should move through the FDA’s approval process more quickly, and this offer CLL patients, more treatment options. Ublituximab is potent monoclonal antibody targeting CD20 similar to obinutizumab. Umbralisib is a new PI3K inhibitor that may have a different and more benign side effect profile than the approved drugs, idelalisib and duvelisib. Here is the link to TG Therapeutic’s press release.